Active substance |
Atezolizumab |
Holder |
Roche |
Status |
Running |
Indication |
In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with stage IV or recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) and whose tumors express PD-L1 < 50% with no EGFR or ALK positive tumors. |
Public documents |
|
Last update |
26/02/2019 |
Tecentriq®
Last updated on 03/04/2024